Ali W. Bseiso MD

Oncology•Stevens Point, WI

Hematologic Oncology

Physician

Join to View Full Profile

4100 State Highway 66Stevens Point, WI 54482
Phone+1 715-343-7700
Fax+1 715-221-6402

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
Boston VA Healthcare System (Brockton-West Roxbury)Residency, Internal Medicine, 1989 - 1992
University of Jordan Faculty of MedicineClass of 1988

Certifications & Licensure

OH State Medical License 2021 - 2025
TX State Medical License 1996 - 2024
WI State Medical License 2000 - 2023
MA State Medical License 1992 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2010 May 01
Completed
Phase 2
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
ACTIVE_NOT_RECRUITING
PHASE2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Mar 10
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

5 citations
Presentation of malignant pleural mesothelioma with symptomatic brain metastasis: report of a case.
Michael Huncharek, Ali W. Bseiso, Lawrence G. Hutchins, John J. Warner
Tumori. 2004-07-01
2 citations
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia
A. W. Bseiso, Hagop M. Kantarjian, J. Q. Guo, Jorge E. Cortes, Moshe Talpaz
Leukemia. 1997-01-01
21 citations
Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia.
A. W. Bseiso, Hagop M. Kantarjian, Eli Estey
Leukemia. 1997-01-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Ali W. Bseiso MD

Dr. Bseiso is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.